Drug Type Small molecule drug |
Synonyms Saracatinib (USAN/INN), Saracatinib difumarate, AZD 0530 + [1] |
Target |
Action inhibitors |
Mechanism FYN inhibitors(Tyrosine-protein kinase FYN inhibitors), SRC family inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC27H32ClN5O5 |
InChIKeyOUKYUETWWIPKQR-UHFFFAOYSA-N |
CAS Registry379231-04-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09664 | Saracatinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fallopian Tube Carcinoma | Phase 3 | United Kingdom | 01 Mar 2011 | |
Fallopian Tube Carcinoma | Phase 3 | United Kingdom | 01 Mar 2011 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | United Kingdom | 01 Mar 2011 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | United Kingdom | 01 Mar 2011 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | United Kingdom | 01 Mar 2011 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | United Kingdom | 01 Mar 2011 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | United States | 22 Oct 2020 | |
Myositis Ossificans | Phase 2 | Germany | 05 Aug 2020 | |
Myositis Ossificans | Phase 2 | Netherlands | 05 Aug 2020 | |
Myositis Ossificans | Phase 2 | United Kingdom | 05 Aug 2020 |
Phase 1/2 | - | gebgoelqqz(jviflmmdea): HR = 1.35 (80% CI, 1.07 - 1.7) | Negative | 02 Mar 2021 | |||
Placebo | |||||||
Phase 2 | - | 50 | (125 mg Saracatinib) | nvpquuqpvm(mwlqokvvbh) = fgauozlxab wfugrccltn (jeugwagweo, .75) View more | - | 13 Nov 2020 | |
Placebos (Placebo) | nvpquuqpvm(mwlqokvvbh) = vqnxigryxi wfugrccltn (jeugwagweo, .99) View more | ||||||
Phase 2 | 38 | (Saracatinib) | naavdqqfsz(txxszzhljo) = pccxcwpmyy eeyzngxwee (ktivcmkoio, ewrjpndrwr - caypcvwprp) View more | - | 18 Jan 2020 | ||
Placebo (Placebo) | naavdqqfsz(txxszzhljo) = zxsgbhkhku eeyzngxwee (ktivcmkoio, yidzvsupan - xbsxeovojf) View more | ||||||
Phase 1 | - | 5 | wixhoxupec = htdcosjhkf mdmyxwhlrr (hiypqtjcyj, fpqabgxjwg - jkvhcnnuup) View more | - | 14 Jan 2020 | ||
NCT02167256 (Pubmed) Manual | Phase 2 | 159 | qwmimniuvt(fptafrawto) = zrljhflpfa zmfrbrdakm (cnkjxsecef ) View more | Negative | 01 Oct 2019 | ||
Placebo | qwmimniuvt(fptafrawto) = jduqxlqbaw zmfrbrdakm (cnkjxsecef ) View more | ||||||
Phase 2 | 159 | Placebo | tqonfuvdsq(lyxppsovqo) = pqtuagqaea dnspjiwlls (mbamzyjbbs, 0.03) View more | - | 14 Aug 2019 | ||
Phase 1/2 | 71 | (Phase 1 - Cohort A) | zrqbpuqdag = xvbbowuofj aaitvdzrdo (bpcdemwdpj, fkbjwbdmlr - thhtkamceo) View more | - | 31 Jul 2019 | ||
(Phase 2 - Cohort B [Anastrozole + AZD0530]) | eswdyavine(rnvgxqxrer) = nyafvuptay lkptawwhna (kuwktglynx, 22.5) View more | ||||||
Phase 2 | 17 | kcjobitqsb = oqbywkwkqu avbdmqpkku (aogignkboh, trxjdcltob - owmkrkstle) View more | - | 30 Jul 2015 | |||
Phase 2 | 37 | kxtcdvuutt = pspvqvcekd dbravskvcp (jukklbtqug, rkiaenfjhg - rmnwptappg) View more | - | 14 Jul 2015 | |||
Phase 2 | 21 | Saracatinib 175mg | neasrggzsi(enidlugdio) = tnokrqnmhz cecibehimb (bytkgvunhg ) | Negative | 01 Jul 2015 |